NEXI-002 is an autologous T cell therapy that generates cytotoxic T cells directed against multiple tumor antigens. These antigens include WT1, CD138, CS1 and NY-ESO-1.
| SparkCures ID | 350 |
|---|---|
| Developed By | NexImmune |
| Generic Name | NEXI-002 |
| Treatment Classifications |
|
| Treatment Targets |
|